Tag: FDA bioequivalence

Why Generics Cost 80-85% Less Than Brand Drugs
Why Generics Cost 80-85% Less Than Brand Drugs

Discover why generic drugs cost 80-85% less than brand names. Learn how patent expiration, reduced R&D costs, and market competition drive these massive savings without compromising quality.

Read More
Bioavailability Studies for Generics: What They Test and Why
Bioavailability Studies for Generics: What They Test and Why

Discover what bioavailability studies test for generic drug approval. Learn how AUC and Cmax determine if a generic is safe and effective compared to brand-name medications.

Read More
Partial AUC: Advanced Bioequivalence Measurements Explained
Partial AUC: Advanced Bioequivalence Measurements Explained

Partial AUC is a refined bioequivalence metric that measures drug exposure during key time windows, not the entire curve. It catches dangerous differences in absorption that traditional tests miss-especially for extended-release and abuse-deterrent generics.

Read More